Mr. Oliveto is a seasoned pharmaceutical executive with more than 25 years of experience in the areas of drug development, commercialization and manufacturing as well as business development, having served as Chief Executive Officer for both public and private companies. Prior to Milestone Pharmaceuticals, Mr. Oliveto was President, CEO and a Director of Chelsea Therapeutics (Nasdaq:CHTP) where he led the company through a successful turnaround which included an NDA filing for, and FDA approval of, Northera™, a drug for the treatment of Neurogenic Orthostatic Hypotension, and the subsequent sale of Chelsea to Lundbeck, Inc. Mr. Oliveto joined Chelsea in 2008 following a two-year assignment as Executive in Residence at Pappas Ventures, a life sciences venture capital firm, where he advised portfolio companies as a board observer and successfully closed multiple follow-on investments.
Prior to Pappas Ventures, he served in a number of progressively senior positions across several operating areas over an 18 year career at Hoffmann-La Roche Inc., most recently as a Global Alliance Director for Roche’s partnering organization. During his tenure, he played an integral part in the success of multiple NDA approvals, development of comprehensive launch programs, including those for both Pegasys and CoPegus, and closed multiple licensing transactions. Mr. Oliveto holds a BA in Chemistry and an MBA, both from Rutgers University.